A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Recruiting

Phase 1

Phase 2

CTX112A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Sponsor:

CRISPR Therapeutics AG

Code:

NCT05643742

Conditions

B-cell Lymphoma

Non-Hodgkin Lymphoma

B-cell Malignancy

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Follicular Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CTX112

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-30. This information was provided to ClinicalTrials.gov by CRISPR Therapeutics AG on 2025-11-14.